Spectrum Pharmaceuticals ($SPPI) rebounds after FDA debacle

By |December 2nd, 2016|Opinions|

Spectrum pharmaceuticals ($SPPI) stock showed strong positive movements in its last trading session. After touching the day high of $4.14, the stock finally closed at $4.10, up 4.86% from its previous close. Spectrum stock is making robust recovery after slumping down to $3.22 price level earlier this month. The company [...]

Premarket Biotech Digest: $JNJ hit with $1 billion fine, $GNVC splits stock, $PFE announces successful Phase 3 trial

By |December 2nd, 2016|Digest|

Spectrum pharmaceuticals ($SPPI) stock showed strong positive movements in its last trading session. After touching the day high of $4.14, the stock finally closed at $4.10, up 4.86% from its previous close. Spectrum stock is making robust recovery after slumping down to $3.22 price [...]

Premarket Biotech Digest – $FLDM jumps, $NVO announces positive results, $ASND reports quarterly loss

By |December 1st, 2016|Digest|

NuVasive Inc. stock is showing signs of recovery from deep slump occurred earlier this month. The stock is likely to have factored in the impact of its weak financial numbers for the third quarter. Aegis has started its coverage of the stock with Buy [...]

NuVasive Inc. ($NUVA) Receives Buy Rating

By |November 30th, 2016|Opinions|

NuVasive Inc. stock is showing signs of recovery from deep slump occurred earlier this month. The stock is likely to have factored in the impact of its weak financial numbers for the third quarter. NuVasive had reported $239.65 million in revenue while its net earnings for the quarter stood at [...]

Premarket Biotech Digest – $CLDX completes acquisition, $ARIA receives FDA approval, $OMCL acquires Ateb

By |November 30th, 2016|Digest|

Sucampo Pharmaceuticals ($SCMP) stock touched $17.20 during its Tuesday trading session. The stock finally closed at $17.20. It is trading close to its 52 weeks high of $18.75. The stock is currently showing strong momentum, having gained over 47% in the past one month. [...]

Premarket Biotech Digest: $GTXI announce positive trial results, $PINC inks a deal, $LLY gets rating downgrade

By |November 29th, 2016|Digest|

Cutera Inc. ($CUTR) jumped to $16.90 in Monday trading session and eventually closed at $16.65. The stock has gained nearly 24% in the past month. Cutera recently announced strong financial numbers for its third quarter. The company reported its revenue at $30.3 million, up [...]

Is Actelion an attractive buy for Johnson & Johnson? $JNJ $ALIOPY

By |November 28th, 2016|Opinions|

Johnson & Johnson $JNJ is reported to be negotiating the acquisition of Swiss pharma company Actelion $ALIOPY. While the company has confirmed that it is engaged in preliminary discussions, it refused to divulge any further information. It is also one of the most prominent biotech companies in Europe. In the [...]

Premarket Biotech Digest – $ZIOP Stock Jumps, $PFE Cuts Investment Plan, $JUNO Halts Drug Study

By |November 28th, 2016|Digest|

• ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock jumped more than 11% in its Friday trading session. The stock’s overall gain during the previous week stood at 6.32%, cutting some of the losses it had incurred in this year so far. Following its recent upswing, the [...]

Three Investment Ideas – November 2016

By |November 26th, 2016|Monthly Investment Ideas|

Halozyme The top three investment angles for Halozyme are that, one, it is a small company with an approved product, two, its Enhanze platform is partnered with a number of large biotech and generates royalties, and three, it has a late stage pipeline with strong potential. Halozyme (HALO) is a [...]

Daily Biotech Digest-$GSK reports positive trial,$AON acquires Admix, $BLUE gets buy rating,

By |November 25th, 2016|Digest|

GlaxoSmithKline (NYSE:GSK) announced that Phase 3 clinical trial assessing asthma med Nucala (mepolizumab) for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) met both co-primary endpoints and all secondary endpoints. • According to Bloomberg, Johnson & Johnson (NYSE:JNJ) has approached Actelion (OTCPK:ALIOY) [...]

Premarket Biotech Digest – $LLY fails Alzheimer test, $NVCN jumps on case closure, $NAVB signs new deal

By |November 24th, 2016|Digest|

Neovasc Inc (NVCN) announced that the U.S. District Court in Massachusetts has granted its motion to dismiss the class action lawsuit Grobler v. Neovasc, et al. (Civil Action No. 16-11038-RGS). The court ruled in favor of the company and its officers on all claims [...]

Pre-Market Biotech Digest-$PDCO misses Q2 forecast, $GSK FDA approval, $AGN acquires Chase Pharma

By |November 24th, 2016|Digest|

Quintiles IMS Holdings Inc (NYSE:Q) announced its new collaboration to provide clearer and more proactive insight into how anti-cancer treatments are used in actual practice across key European markets. The study will involve the use of Pfizer (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY), Merck KGaA (OTCPK:MKGAF)(OTCPK:MKGAY) [...]

Premarket Biotech Digest: $IMUC Data Spike, $ROGS New Collaboration, $AZN Hold Lifted

By |November 22nd, 2016|Digest|

ImmunoCellular Therapeuticals (NYSEMKT:IMUC) stock jumped 25% in the Monday trading session as the company announced the latest data for the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma. The updated immune response data from the phase 2 trial showed that treatment [...]

Premarket Biotech Digest: $VRX Related Fraud, $AZN $AGN $1.5bn Licensing Deal, $CYCC Positive Data

By |November 18th, 2016|Digest|

Valeant's liaison with Philidor paid millions to promote Philidor interest, including acquisition option Valeant (VRX) is entangled in a legal tangle. Details are emerging that former VRX and Philidor liason Gary Tanner was paid up to $10mn by Philidor through CEO Andrew Davenport to [...]

Premarket Biotech Digest: $AMGN Positive, $GILD Mixed Results, $SRNE Acquires

By |November 17th, 2016|Digest|

Amgen's erenumab shows positive results in second late-stage migraine study - $AMGN phase 3 STRIVE study has shown positive results in migraine patients, meeting primary endpoint of statistically valid change from baseline in mean monthly migraine days at week 24 compared to placebo.It was [...]

Premarket Biotech Digest: $ACAD New Trial, $ITEK Catalyst, $JAZZ Insider Buy

By |November 16th, 2016|Digest|

According to my biotech stock screener, Inotek $ITEK is trading near its 52-week low, has total cash of $137 million and a market cap of only $185 million (these figures could be wrong, please fact check), and has an upcoming catalyst, results for Trabodenoson [...]

Premarket Biotech Digest: $GALT Announces Positive Results, $PFE Considers Sale of Consumer Health Business, $ANTH Fails in Lupus Study

By |November 11th, 2016|Digest|

Focus Ticker: Galectin Therapeutics Galectin Therapeutics $GALT announced on Thursday that it observed positive results from its Phase 2a clinical trial, evaluating lead product candidate GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis. All five subjects, who took the treatment with 8 mg/kg of GR-MD-02 administered every other week showed [...]

Biotech Trade Alerts Archive -2016-11-10- $DMTX, $BMY, $ANTH, $TENX, $AZN, $PFE

By |November 11th, 2016|Real Time Trade Alerts|

DRKKD.com Real Time Biotech Trade Alert Service November 10, 2016. Tickers covered: DMTX, BMY, ANTH, TENX, AZN, PFE *** L3 or above subscription required to read further... Login or Subscribe/Upgrade here Posted: Thu, 10 Nov 2016 09:53:06 -0500 Ticker: DMTX InPortfolio: No ConvictionBuy: No Price: 4.50 RiskProfile: High [...]

$DMTX reports Q3 results

By |November 10th, 2016|News|

Dimension Therapeutics $DMTX reported Q3 EPS of -$0.58, missing the guidance by $0.03. Revenue was $2.76 million, a growth of 34%, Y-o-Y, and beating the estimate by $0.6 million.

$BMY signs global licensing agreement with Nitto Denko

By |November 10th, 2016|News|

Bristol-Myers Squibb $BMY signed a global licensing agreement with Japanese firm Nitto Denko $NDEKF for the development and commercialization of Nitto�s siRNA molecules targeting heat shock protein 47 (HSP47) formulations containing vitamin A. The agreement includes Nitto�s lead product candidate, Phase 1b-stage ND-L02-s0201, for the treatment of advanced liver fibrosis [...]

s2Member®